Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Laryngoscope ; 132(4): 801-805, 2022 04.
Article in English | MEDLINE | ID: mdl-34427325

ABSTRACT

OBJECTIVES/HYPOTHESIS: Early-stage laryngeal squamous cell carcinoma (LSCC) has yielded local control rates of 75% after radiotherapy. DNA methylation, in which DNA methyltransferases play an important role, has influence on tumorigenesis. In this study, we investigated the association between the expression of DNA methyltransferase 1 (DNMT1) and local control in early-stage LSCC treated with radiotherapy. STUDY DESIGN: Retrospective cohort study. METHODS: We analyzed a well-defined homogeneous series of 125 LSCC patients treated with radiotherapy with curative intent. The association of immunohistochemical expression of DNMT1 with local control was evaluated using Cox proportional hazard regression models. RESULTS: With a median follow-up of 58 months, 29 local recurrences (23%) were observed. On univariate analysis, worse local control was associated with high DNMT1 expression (hazard ratio [HR] 2.57, 95% confidence interval [CI] 1.10-6.01). Also, higher T-stage (HR 2.48, 95% CI 1.06-5.80) and positive N-status (HR 2.62, 95% CI 1.06-6.47) were associated with worse local control. Multivariate Cox regression demonstrated that high DNMT1 (HR 2.81; 95% CI 1.20-6.58) was independently associated with worse local control. CONCLUSIONS: We found an association between high DNMT1 expression and worse local control in a homogeneous well-defined cohort of early-stage LSCC patients treated with definitive radiotherapy. The association between DNA methylation status as determined by DNMT1 expression and local control suggests that DNMT1 acts as a potential prognostic tumor marker in treatment decision-making in early-stage laryngeal carcinoma. LEVEL OF EVIDENCE: NA Laryngoscope, 132:801-805, 2022.


Subject(s)
Carcinoma, Squamous Cell , Head and Neck Neoplasms , Laryngeal Neoplasms , Carcinoma, Squamous Cell/genetics , Carcinoma, Squamous Cell/metabolism , Carcinoma, Squamous Cell/radiotherapy , DNA , Head and Neck Neoplasms/pathology , Humans , Laryngeal Neoplasms/genetics , Laryngeal Neoplasms/metabolism , Laryngeal Neoplasms/radiotherapy , Neoplasm Staging , Prognosis , Retrospective Studies , Squamous Cell Carcinoma of Head and Neck/pathology
2.
PLoS One ; 14(7): e0220211, 2019.
Article in English | MEDLINE | ID: mdl-31339938

ABSTRACT

Spinal Muscular Atrophy (SMA) is a disorder characterized by the degeneration of motor neurons in the spinal cord, leading to muscular atrophy. In the majority of cases, SMA is caused by the homozygous absence of the SMN1 gene. The disease severity of SMA is strongly influenced by the copy number of the closely related SMN2 gene. In addition, an SMN variant lacking exons 7 and 8 has been reported in 8% and 23% of healthy Swedish and Spanish individuals respectively. We tested 1255 samples from the 1000 Genomes Project using a new version of the multiplex ligation-dependent probe amplification (MLPA) P021 probemix that covers each SMN exon. The SMN variant lacking exons 7 and 8 was present in up to 20% of individuals in several Caucasian populations, while being almost completely absent in various Asian and African populations. This SMN1/2Δ7-8 variant appears to be derived from an ancient deletion event as the deletion size is identical in 99% of samples tested. The average total copy number of SMN1, SMN2 and the SMN1/2Δ7-8 variant combined was remarkably comparable in all populations tested, ranging from 3.64 in Asian to 3.75 in African samples.


Subject(s)
Muscular Atrophy, Spinal/epidemiology , Muscular Atrophy, Spinal/genetics , Survival of Motor Neuron 1 Protein/genetics , Cells, Cultured , DNA Copy Number Variations , Ethnicity/genetics , Ethnicity/statistics & numerical data , Exons/genetics , Female , Gene Frequency , Genetics, Population , Geography , Humans , Male , Polymorphism, Genetic , Sequence Deletion , Survival of Motor Neuron 2 Protein/genetics
3.
Mol Diagn Ther ; 20(4): 363-74, 2016 08.
Article in English | MEDLINE | ID: mdl-27278367

ABSTRACT

INTRODUCTION: Fibroblast growth factor receptor family member proteins (FGFR1-4) have been identified as promising novel therapeutic targets and prognostic markers in a wide spectrum of solid tumors. The present study investigates the expression and prognostic value of four FGFR family member proteins in a large multicenter oral cavity squamous cell carcinoma (OCSCC) and oropharyngeal squamous cell carcinoma (OPSCC) cohort. METHODS: Protein expression of FGFR1-4 was determined by immunohistochemistry on tissue microarrays containing 951 formalin-fixed paraffin embedded OCSCC and OPSCC tissues from the University Medical Center Utrecht and University Medical Center Groningen. Protein expression was correlated to overall survival using Cox regression models, and bootstrapping was performed as internal validation. RESULTS: FGFR proteins were highly expressed in 39-64 % of OCSCC and 63-79 % of OPSCC. Seventy-three percent (299/412) of OCSCC and 85 % (305/357) of OPSCC highly co-expressed two or more FGFR family member proteins. FGFR1 protein was more frequently highly expressed in human papillomavirus (HPV)-negative OPSCC than HPV-positive OPSCC (82 vs. 65 %; p = 0.008). Furthermore, protein expression of FGFR family members was not related to overall survival in OCSCC or OPSCC (p > 0.05). CONCLUSION: FGFR family members are frequently highly expressed in OCSCC and OPSCC. These FGFR family member proteins are therefore potential targets for novel therapies that are urgently required to improve survival of OCSCC and OPSCC patients.


Subject(s)
Carcinoma, Squamous Cell/metabolism , Carcinoma, Squamous Cell/mortality , Mouth Neoplasms/metabolism , Mouth Neoplasms/mortality , Oropharyngeal Neoplasms/metabolism , Oropharyngeal Neoplasms/mortality , Receptors, Fibroblast Growth Factor/metabolism , Adult , Aged , Aged, 80 and over , Biomarkers, Tumor , Carcinoma, Squamous Cell/diagnosis , Carcinoma, Squamous Cell/therapy , Combined Modality Therapy , Female , Gene Expression , Humans , Immunohistochemistry , Kaplan-Meier Estimate , Male , Middle Aged , Mouth Neoplasms/diagnosis , Mouth Neoplasms/therapy , Multigene Family , Neoplasm Grading , Neoplasm Staging , Oropharyngeal Neoplasms/diagnosis , Oropharyngeal Neoplasms/therapy , Prognosis , Receptors, Fibroblast Growth Factor/genetics , Young Adult
4.
Genes Chromosomes Cancer ; 55(1): 45-59, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26391330

ABSTRACT

Lymph node (LN) metastasis is the most important prognostic factor in oral squamous cell carcinoma (OSCC) patients. However, in approximately one third of OSCC patients nodal metastases remain undetected, and thus are not adequately treated. Therefore, clinical assessment of LN metastasis needs to be improved. The purpose of this study was to identify DNA methylation biomarkers to predict LN metastases in OSCC. Genome wide methylation assessment was performed on six OSCC with (N+) and six without LN metastases (N0). Differentially methylated sequences were selected based on the likelihood of differential methylation and validated using an independent OSCC cohort as well as OSCC from The Cancer Genome Atlas (TCGA). Expression of WISP1 using immunohistochemistry was analyzed on a large OSCC cohort (n = 204). MethylCap-Seq analysis revealed 268 differentially methylated markers. WISP1 was the highest ranking annotated gene that showed hypomethylation in the N+ group. Bisulfite pyrosequencing confirmed significant hypomethylation within the WISP1 promoter region in N+ OSCC (P = 0.03) and showed an association between WISP1 hypomethylation and high WISP1 expression (P = 0.01). Both these results were confirmed using 148 OSCC retrieved from the TCGA database. In a large OSCC cohort, high WISP1 expression was associated with LN metastasis (P = 0.05), disease-specific survival (P = 0.022), and regional disease-free survival (P = 0.027). These data suggest that WISP1 expression is regulated by methylation and WISP1 hypomethylation contributes to LN metastasis in OSCC. WISP1 is a potential biomarker to predict the presence of LN metastases.


Subject(s)
CCN Intercellular Signaling Proteins/genetics , Carcinoma, Squamous Cell/genetics , Carcinoma, Squamous Cell/pathology , DNA Methylation , Mouth Neoplasms/genetics , Mouth Neoplasms/pathology , Proto-Oncogene Proteins/genetics , Adult , Aged , Aged, 80 and over , CCN Intercellular Signaling Proteins/metabolism , Carcinoma, Squamous Cell/metabolism , Epigenesis, Genetic , Female , Gene Expression Regulation, Neoplastic , Humans , Lymphatic Metastasis , Male , Middle Aged , Mouth Neoplasms/metabolism , Prognosis , Promoter Regions, Genetic , Proto-Oncogene Proteins/metabolism , Sequence Analysis, DNA , Survival Analysis
5.
Int J Radiat Oncol Biol Phys ; 90(2): 454-62, 2014 Oct 01.
Article in English | MEDLINE | ID: mdl-25304797

ABSTRACT

PURPOSE: To assess the prevalence of EGFRvIII, a specific variant of EGFR (epidermal growth factor receptor), in 3 well-defined cohorts of head and neck squamous cell carcinoma (HNSCC). METHODS AND MATERIALS: Immunohistochemistry for the specific detection of EGFRvIII using the L8A4 antibody was optimized on formalin-fixed, paraffin-embedded tissue using glioblastoma tissue. It was compared with EGFR and EGFRvIII RNA expression using a specific reverse transcription-polymerase chain reaction also optimized for formalin-fixed, paraffin-embedded tissue. Tissue microarrays including 531 HNSCCs of various stages with complete clinicopathologic and follow-up data were tested for the presence of EGFRvIII. RESULTS: None of the 531 cases showed EGFRvIII protein expression. Using an immunohistochemistry protocol reported by others revealed cytoplasmic staining in 8% of cases. Reverse transcription-polymerase chain reaction for the EGFRvIII transcript of the 28 highest cytoplasmic staining cases, as well as 69 negative cases, did not show expression in any of the tested cases, suggesting aspecific staining by a nonoptimal protocol. CONCLUSIONS: The EGFRvIII mutation is not present in HNSCC. Therefore, EGFRvIII does not influence treatment response in HNSCC and is not a usable clinical prognostic marker.


Subject(s)
Carcinoma, Squamous Cell/metabolism , ErbB Receptors/analysis , Head and Neck Neoplasms/metabolism , Neoplasm Proteins/analysis , Adult , Aged , Aged, 80 and over , Cohort Studies , ErbB Receptors/genetics , Female , Humans , Immunohistochemistry , Male , Middle Aged , Mutation , Neoplasm Proteins/genetics , RNA/analysis , Reverse Transcriptase Polymerase Chain Reaction , Squamous Cell Carcinoma of Head and Neck , Tissue Array Analysis/methods
6.
Stem Cells Dev ; 20(12): 2037-51, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21838536

ABSTRACT

Increasing evidence shows that neural stem/progenitor cells (NSPCs) can be activated in the nonconventional neurogenic zones such as the cortex following ischemic stroke. However, the precise origin, identity, and subtypes of the ischemia-induced NSPCs (iNSPCs), which can contribute to cortical neurogenesis, is currently still unclear. In our present study, using an adult mouse cortical infarction model, we found that the leptomeninges (pia mater), which is widely distributed within and closely associated with blood vessels as microvascular pericytes/perivascular cells throughout central nervous system (CNS), have NSPC activity in response to ischemia and can generate neurons. These observations indicate that microvascular pericytes residing near blood vessels that are distributed from the leptomeninges to the cortex are potential sources of iNSPCs for neurogenesis following cortical infarction. In addition, our results propose a novel concept that the leptomeninges, which cover the entire brain, have an important role in CNS restoration following brain injury such as stroke.


Subject(s)
Brain Infarction/pathology , Cerebral Cortex/blood supply , Cerebral Cortex/pathology , Neural Stem Cells/pathology , Pia Mater/blood supply , Pia Mater/pathology , Animals , Biomarkers/metabolism , Brain Infarction/complications , Brain Infarction/metabolism , Cell Proliferation , Cerebral Cortex/metabolism , Intermediate Filament Proteins/metabolism , Male , Mice , Microvessels/metabolism , Microvessels/pathology , Models, Biological , Nerve Tissue Proteins/metabolism , Nestin , Neural Stem Cells/metabolism , Neurons/metabolism , Neurons/pathology , Pericytes/metabolism , Pericytes/pathology , Pia Mater/metabolism , Stroke/complications , Stroke/metabolism , Stroke/pathology
7.
Neuroreport ; 22(16): 789-94, 2011 Nov 16.
Article in English | MEDLINE | ID: mdl-21862939

ABSTRACT

Adult brain-derived neural stem cells have acquired a lot of interest as an endurable neuronal cell source that can be used for central nervous system repair in a wide range of neurological disorders such as ischemic stroke. Recently, we identified injury-induced neural stem/progenitor cells in the poststroke murine cerebral cortex. In this study, we show that, after differentiation in vitro, injury-induced neural stem/progenitor cells express pyramidal cell markers Emx1 and CaMKIIα, as well as mature neuron markers MAP2 and Tuj1. 5-bromo-2-deoxyuridinine-positive neurons in the peristroke cortex also express such pyramidal markers. The presence of newly regenerated pyramidal neurons in the poststroke brain might provide a noninvasive therapeutic strategy for stroke treatment with functional recovery.


Subject(s)
Brain Ischemia/metabolism , Cerebral Cortex/metabolism , Neural Stem Cells/metabolism , Neurogenesis/physiology , Pyramidal Cells/metabolism , Animals , Biomarkers/metabolism , Brain Ischemia/pathology , Cerebral Cortex/pathology , Disease Models, Animal , Male , Mice , Mice, SCID , Neural Stem Cells/pathology , Primary Cell Culture , Pyramidal Cells/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...